Home/Filings/4/0001209191-17-009269
4//SEC Filing

FIVE PRIME THERAPEUTICS INC 4

Accession 0001209191-17-009269

CIK 0001175505operating

Filed

Feb 8, 7:00 PM ET

Accepted

Feb 9, 7:18 PM ET

Size

9.6 KB

Accession

0001209191-17-009269

Insider Transaction Report

Form 4
Period: 2017-02-07
Baker Kevin Paul
SVP, Development Sciences
Transactions
  • Award

    Common Stock

    2017-02-07+5,62588,389 total
  • Award

    Employee Stock Option (right to buy)

    2017-02-07+25,00025,000 total
    Exercise: $45.38Exp: 2027-02-06Common Stock (25,000 underlying)
  • Award

    Common Stock

    2017-02-07+7,03195,420 total
Footnotes (4)
  • [F1]Represents shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on each of February 5, 2018, 2019 and 2020, provided the reporting person provides services to Five Prime Therapeutics, Inc. through each such date.
  • [F2]Includes 264 shares of common stock granted to the reporting person by Five Prime Therapeutics, Inc. pursuant to a company match under Five Prime Therapeutics, Inc.'s 401(k) plan.
  • [F3]Represents shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on February 5, 2019 and two-thirds (2/3) of the restricted stock will vest on February 5, 2020, provided the reporting person provides services to Five Prime Therapeutics, Inc. through each such date.
  • [F4]The shares underlying the option vest at a rate of one forty-eighth (1/48th) per month beginning on March 7, 2017, provided the reporting person provides services to Five Prime Therapeutics, Inc. through each such date.

Issuer

FIVE PRIME THERAPEUTICS INC

CIK 0001175505

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001175505

Filing Metadata

Form type
4
Filed
Feb 8, 7:00 PM ET
Accepted
Feb 9, 7:18 PM ET
Size
9.6 KB